Home World News CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients... World News CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas By Ogkologos - July 16, 2026 230 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 10-year follow-up of a phase II study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients... December 9, 2024 Έγκριση νέας επικουρικής θεραπείας για τον θετικά πρώιμο καρκίνο του μαστού June 24, 2019 Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation June 5, 2024 2026 Heine H. Hansen Award Recipient Announced February 3, 2026 Load more HOT NEWS Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and... FLT3 Internal Tandem Duplication Measurable Residual Disease in Complete Remission Identifies... For AYAs with Advanced Cancer, Study Finds Serious Communication Gaps about... What to Do When You Are Diagnosed With Cancer During Pregnancy
